Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

BACKGROUND: Treatments for Hepatitis C virus (HCV) infection have vastly improved over the past few decades with current regimens now offering pangenotypic activity with excellent cure rates reported in clinical trials, including in the HIV-HCV coinfected population. However, there is some concern t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Infect Dis
Autors principals: Maughan, A., Sadigh, K., Angulo-Diaz, V., Mandimika, C., Villanueva, M., Lim, J. K., Ogbuagu, O.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500032/
https://ncbi.nlm.nih.gov/pubmed/31053098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-3974-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars